A Pharmacokinetic Comparison of Adult and Paediatric Formulations of Raltegravir in Healthy Adults

  title={A Pharmacokinetic Comparison of Adult and Paediatric Formulations of Raltegravir in Healthy Adults},
  author={Elizabeth G. Rhee and Matthew L. Rizk and Diana M. Brainard and Isaias Noel Gendrano and Bo Jin and Larissa A. Wenning and John A. Wagner and Marian Iwamoto},
  journal={Antiviral Therapy},
  pages={619 - 624}
Background Raltegravir is an HIV-1 integrase inhibitor approved for use in adults, children and infants ≥4 weeks of age. As alternatives to the original film-coated tablet, a chewable ethylcellulose (EC) tablet and oral granules for suspension (GFS) have been developed for use in children. The purpose of this study was to evaluate these formulations in adults prior to use in paediatric studies. Methods This open-label, 4-period, randomized, crossover study investigated the safety, tolerability… 

Figures and Tables from this paper

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.
A total of 6 mg/kg per dose twice daily of RAL for oral suspension was well tolerated and showed favorable virologic and immunologic responses.
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV‐infected children 4 weeks to 18 years of age
Raltegravir chewable tablets and oral granules exhibited PK parameters consistent with those from prior adult studies and older children in P1066, as well as lower variability than the film‐coated tablet.
The role of formulation on the pharmacokinetics of antiretroviral drugs
This review provides an overview of studies assessing the pharmacokinetics of different antiretroviral drug formulations in adults and children, including fixed-dose combinations, with largest differences in exposure when a liquid formulation is compared to a capsule formulation.
Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents
This work is distributed under the terms of the License http://creativecommons.org/licenses/by-nc/3.0/.
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling
This study aimed to develop and evaluate maternal–fetal physiologically based pharmacokinetic models for two antiretroviral drugs, dolutegravir and ralteg Gravir, and to evaluate their effects on placental drug transfer.
Making things easier. How to improve antiviral drug treatment for children
Whether once-daily lopinavir/ritonavir is noninferior to twice-daily (b.i.d.) dosing in children is evaluated.


Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
  • S. Nachman, N. Zheng, A. Wiznia
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
Raltegravir as a film-coated tablet 400 mg twice daily and chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily was well tolerated and showed favorable virologic and immunologic responses.
Effect of Low‐, Moderate‐, and High‐Fat Meals on Raltegravir Pharmacokinetics
A more detailed analysis of the effects of different meal types (low, moderate, and high fat content) on the plasma pharmacokinetic profile of raltegravir is described.
Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients
Findings emphasize the importance of the shape of the plasma concentration-versus-time curve for long-term efficacy in HIV-infected patients.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
In HIV-infected patients with limited treatment options, raltegravir plus optimization background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks.
Clinical Pharmacology Profile of Raltegravir, an HIV‐1 Integrase Strand Transfer Inhibitor
Raltegravir demonstrates favorable clinical pharmacology and a drug interaction profile that permits administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment.
Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.
Interim results from IMPAACT P1066: raltegravir oral granule formulation in children 6 months to <2 years
  • 19th Conference on Retroviruses and Opportunistic Infections
  • 2012
Pharmacokinetics and pharmacodynamics of once - daily versus twice - daily raltegravir in treatmentnaive HIV - infected patients
  • J Clin Pharmacol
  • 2011
Safety and efficacy of raltegravirbased versus efavirenzbased combination therapy in treatmentnaive patients with HIV - 1 infection : a multicentre , double - blind randomised controlled trial
  • N Engl J Med
  • 2008